Updates

Eagle Eye

October 2020

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Eagle Eye has issued full year results to end June, with sales up 21% to £20.4m. Pretax profit was £0.1m versus a £2m loss. Adjusting for VAT and PAYE deferrals and so on, net cash burn fell sharply from £1.9m last year to £0.6m. With £1.5m cash and a £5m facility, it says it is fully funded.With the Nectar programme and Loblaw accounting for the bulk of the 2.1bn iterations over the platform in the form of low value loyalty transactions (with each generating part pence), transaction fees were up a third to £6m. But other recurring elements - licence (£7.7m +38%) and SMS fees (£1.2m) - bumped up overall recurring revenues to £14.9m - ie. 73% of sales.Speaking t ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Kape

SimplyBiz

Eagle Eye (February 2023)

Eagle Eye - Wins further North American business (March 2022)

Eagle Eye (April 2021)

Eagle Eye (December 2019)

Eagle Eye - Moves to EBITDA profitability (August 2019)

Eagle Eye - Shares well off the 316p high; 72% recurring fees (June 2019)

Eagle Eye - Positive EBITDA expected for H2 (April 2019)

Eagle Eye (December 2018)

Eagle Eye (August 2017)

Eagle Eye (July 2017)

Eagle Eye - Strong momentum with tier 1 retailers continues (June 2017)

Eagle Eye - Coupon redemption volumes rise to 4m a month in February (May 2017)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X